<DOC>
	<DOCNO>NCT02268474</DOCNO>
	<brief_summary>A single center prospective , randomize , control split face study compare 532nm KTP laser 595nm PDL treatment Erythematotelangiectatic Rosacea Papulopustular Rosacea . Subjects receive 3 laser treatment 4 week apart follow 4 6 week post-final laser treatment .</brief_summary>
	<brief_title>Excel V 532 nm KTP Laser Treatment Erythematotelangiectatic Rosacea &amp; Papulopustular Rosacea</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<mesh_term>Chlorhexidine</mesh_term>
	<mesh_term>Chlorhexidine gluconate</mesh_term>
	<criteria>1 . Females Males , 20 80 year age ( inclusive ) . 2 . Fitzpatrick Skin Type I III . 3 . Clinical diagnosis Erythematotelangiectatic Rosacea Papulopustular Rosacea . 4 . Willing refrain use systemic corticosteroid retinoids ; topical corticosteroid retinoids treat area . 5 . Must able read , understand sign Informed Consent Form . 6 . Must willing able adhere treatment followup schedule posttreatment care instruction . 7 . Wiling limited sun exposure use approve sunscreen SPF 50 high face every day duration study , include followup period . 8 . Willingness digital photograph take face . 9 . Agree undergo procedure treatment Erythematotelangiectatic Rosacea Papulopustular Rosacea study . 10 . Postmenopausal surgically sterilize , use medically acceptable form birth control least 3 month prior enrollment entire course study . 1 . History prior laser light base procedure face within 6 month study participation . 2 . Fitzpatrick Skin Type IV VI . 3 . Pregnant and/or breastfeeding . 4 . Subject le 20 year age great 80 year age . 5 . Having infection , dermatitis rash treatment area . 6 . Suffering significant concurrent illness , diabetes mellitus , cardiovascular disease , uncontrolled hypertension , pertinent neurological disorder . 7 . History keloid formation , hypertrophic scar abnormal wound healing . 8 . History immunosuppression/immune deficiency disorder psoriasis , eczema , vitiligo , currently use immunosuppressive medication . 9 . Malignant tumor target area history malignant skin disease . 10 . History fibromyalgia . 11 . History connective tissue disease , systemic lupus erythematosus scleroderma . 12 . Having know anticoagulative condition take prescription anticoagulation medication . 13 . History seizure disorder due light . 14 . Any current use medication know increase sensitivity light , tetracycline . 15 . Having history disease stimulate heat , recurrent herpes simplex treatment area , unless treatment conduct follow prophylactic regimen . 16 . Having undergone surgery treatment area within 6 month treatment ( skin heal completely ) . 17 . History radiation head , neck and/or upper chest . 18 . History pigmentary disorder , particularly tendency hyper hypopigmentation . 19 . Undergoing systemic chemotherapy treatment cancer . 20 . Systemic use retinoid isotretinoin and/or corticosteroid within 6 month . 21 . Topical use retinoid and/or corticosteroid within 4 week study participation . 22 . Any use gold therapy disorder rheumatologic disease lupus . 23 . Excessively tanned area treat unable/unlikely refrain tan study . 24 . Current smoker history smoking within 12 month study participation . 25 . Participation study another device drug within 6 month prior enrollment study . 26 . As per Investigator 's discretion , physical mental condition might make unsafe subject participate study .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>532nm</keyword>
	<keyword>Excel V</keyword>
	<keyword>Cutera</keyword>
	<keyword>Laser</keyword>
	<keyword>Laser Light</keyword>
	<keyword>PDL</keyword>
	<keyword>595nm</keyword>
	<keyword>Flash Lamp</keyword>
</DOC>